TY - JOUR

T1 - EAACI guideline

T2 - Anaphylaxis (2021 update)

AU - Muraro, Antonella

AU - Worm, Margitta

AU - Alviani, Cherry

AU - Cardona, Victoria

AU - DunnGalvin, Audrey

AU - Garvey, Lene H.

AU - Riggioni, Carmen

AU - Silva, Debra de

AU - Angier, Elizabeth

AU - Arasi, Stefania

AU - Bellou, Abdelouahab

AU - Beyer, Kirsten

AU - Bijlhout, Diola

AU - Bilò, M. Beatrice

AU - Bindslev-Jensen, Carsten

AU - Brockow, Knut

AU - Fernandez-Rivas, Montserrat

AU - Halken, Susanne

AU - Jensen, Britt

AU - Khaleva, Ekaterina

AU - Michaelis, Louise J.

AU - Elberink, Hanneke N. G. Oude

AU - Regent, Lynne

AU - Sanchez, Angel

AU - Vlieg-Boerstra, Berber J.

AU - Roberts, Graham

PY - 2022

Y1 - 2022

N2 - Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.

AB - Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.

KW - adults

KW - Anaphylaxis

KW - children

KW - guidelines

U2 - 10.1111/all.15032

DO - 10.1111/all.15032

M3 - Journal article

C2 - 34343358

VL - 77

SP - 357

EP - 377

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 2

ER -